Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply

MLA

John Bridgewater, et al. “Second-Line FOLFOX Chemotherapy for Advanced Biliary Tract Cancer – Authors’ Reply.” The Lancet Oncology, vol. 22, July 2021, pp. e288–89. EBSCOhost, https://doi.org/10.1016/s1470-2045(21)00341-7.

APA

John Bridgewater, Stephen Falk, Kinnari Patel, Alan Anthoney, Harpreet Wasan, W David J Ryder, Safia Barber, Juan W. Valle, Daniel H. Palmer, Yuk Ting Ma, Roopinder Gillmore, Arvind Arora, Jonathan Wadsley, John Ramage, Angela Lamarca, Claire Hobbs, Timothy Iveson, Justin S. Waters, Linda Davies, … Anthony Maraveyas. (2021). Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors’ reply. The Lancet Oncology, 22, e288–e289. https://doi.org/10.1016/s1470-2045(21)00341-7

Chicago

John Bridgewater, Stephen Falk, Kinnari Patel, Alan Anthoney, Harpreet Wasan, W David J Ryder, Safia Barber, et al. 2021. “Second-Line FOLFOX Chemotherapy for Advanced Biliary Tract Cancer – Authors’ Reply.” The Lancet Oncology 22 (July): e288–89. doi:10.1016/s1470-2045(21)00341-7.